Overview

Rapamycin vs Methotrexate in Diffuse SSc

Status:
Completed

Trial end date:
2006-06-01

Target enrollment:

Participant gender:

Summary

This is a study to determine the safety of the immunosuppressive rapamycin in patients with systemic sclerosis with diffuse cutaneous scleroderma. The effects (both good and bad) are being compared to another group of systemic sclerosis patients receiving methotrexate

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of California, Los Angeles

Treatments:

Everolimus
Methotrexate
Sirolimus